These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37239841)

  • 1. Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice.
    Inia JA; Stokman G; Morrison MC; Worms N; Verschuren L; Caspers MPM; Menke AL; Petitjean L; Chen L; Petitjean M; Jukema JW; Princen HMG; van den Hoek AM
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
    van den Hoek AM; Verschuren L; Worms N; van Nieuwkoop A; de Ruiter C; Attema J; Menke AL; Caspers MPM; Radhakrishnan S; Salic K; Kleemann R
    Cells; 2020 Sep; 9(9):. PubMed ID: 32883049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
    Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
    Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
    Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
    Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study on roles of natural killer T cells in two diet-induced non-alcoholic steatohepatitis-related fibrosis in mice.
    Zheng S; Yang W; Yao D; Tang S; Hou J; Chang X
    Ann Med; 2022 Dec; 54(1):2233-2245. PubMed ID: 35950602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Dose Administration of Cannabigerol Attenuates Inflammation and Fibrosis Associated with Methionine/Choline Deficient Diet-Induced NASH Model via Modulation of Cannabinoid Receptor.
    Aljobaily N; Krutsinger K; Viereckl MJ; Joly R; Menlove B; Cone B; Suppes A; Han Y
    Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intervention with isoleucine or valine corrects hyperinsulinemia and reduces intrahepatic diacylglycerols, liver steatosis, and inflammation in Ldlr-/-.Leiden mice with manifest obesity-associated NASH.
    Gart E; van Duyvenvoorde W; Caspers MPM; van Trigt N; Snabel J; Menke A; Keijer J; Salic K; Morrison MC; Kleemann R
    FASEB J; 2022 Aug; 36(8):e22435. PubMed ID: 35830259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
    J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
    Møllerhøj MB; Veidal SS; Thrane KT; Oró D; Overgaard A; Salinas CG; Madsen MR; Pfisterer L; Vyberg M; Simon E; Broermann A; Vrang N; Jelsing J; Feigh M; Hansen HH
    Clin Transl Sci; 2022 May; 15(5):1167-1186. PubMed ID: 35143711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk.
    van den Hoek AM; de Jong JCBC; Worms N; van Nieuwkoop A; Voskuilen M; Menke AL; Lek S; Caspers MPM; Verschuren L; Kleemann R
    Metabolism; 2021 Nov; 124():154873. PubMed ID: 34478753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
    Choi YJ; Johnson JD; Lee JJ; Song J; Matthews M; Hellerstein MK; McWherter CA
    Am J Physiol Gastrointest Liver Physiol; 2024 Feb; 326(2):G120-G132. PubMed ID: 38014444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-Inactivated
    Morrison MC; Gart E; Duyvenvoorde WV; Snabel J; Nielsen MJ; Leeming DJ; Menke A; Kleemann R
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis.
    Hsieh YC; Wu PS; Lin YT; Huang YH; Hou MC; Lee KC; Lin HC
    FASEB J; 2022 Oct; 36(10):e22526. PubMed ID: 36063123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice.
    Morrison MC; Mulder P; Salic K; Verheij J; Liang W; van Duyvenvoorde W; Menke A; Kooistra T; Kleemann R; Wielinga PY
    Int J Obes (Lond); 2016 Sep; 40(9):1416-23. PubMed ID: 27121255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide alters gut microbiota and improves NAFLD in db/db mice.
    Mao T; Zhang C; Yang S; Bi Y; Li M; Yu J
    Biochem Biophys Res Commun; 2024 May; 710():149882. PubMed ID: 38583231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.